Investigations on isatin-pyrimidinone hybrids as novel lead compounds for selective inhibition of TrkA enzyme
Bioorganic Chemistry · 2026-06 · 174 · 109718
DOI: 10.1016/j.bioorg.2026.109718 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-06. Verfasst von Basma S Abdulrazik und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, The Faculty of Pharmacy, The British University in Egypt (BUE), El-Sherouk City, Cairo 11837, Egypt; Drug Res…. Hauptthemen laut MEDLINE: Pyrimidinones, Antineoplastic Agents, Receptor, trkA, Protein Kinase Inhibitors. Die Arbeit nennt 128 Literaturangaben. Gefördert von: Al-Azhar University.
Abstract (Originalsprache)
Cancer remains one of the most significant health challenges worldwide. Despite the continuous development of anticancer drugs, the battle against cancer persists due to frequent mutations. Tropomyosin receptor kinase A (TrkA) is considered one of the promising targets in cancer therapy. The urge to overcome drug resistance has prioritized the need for synthesizing potent TrkA inhibitors. In this study, we synthesized a series of sixteen novel pyrimidinone derivatives that showed potent activity against the TrkA enzyme using sequential chemical reactions. The targeted compounds were screened in vitro using an MTT assay against three cell lines, including HepG2, MCF-7, and K-562. Some of the screened compounds exhibited good antitumor activity, such as compound 6m, which showed more potent activity against the MCF-7 cell line, with an IC50 of 19.1 μM, compared to 24.2 μM for 5-fluorouracil, a reference drug. Furthermore, cell cycle and apoptosis assays were performed to confirm the induction of cell cycle arrest in the G1 phase in addition to their potent antiproliferative effects. In addition, an enzyme inhibition assay was performed for all prepared compounds against the TrkA enzyme. Compounds 6b, 6i, 6j, and 6n exhibited the most preferable activity, with IC50 values of 8.9, 8.9, 8.0, and 6.6 μM, respectively, compared to Sorafenib (IC50 = 0.6 μM), serving as a control drug. Moreover, in silico computational studies, such as molecular docking and ADME predictions, were done to predict the ligand-protein interactions, physicochemical properties, and oral bioavailability of the proposed compounds.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Chemistry, The Faculty of Pharmacy, The British University in Egypt (BUE), El-Sherouk City, Cairo 11837, Egypt; Drug Research and Development Group (DRD-G), The British University in Egypt,…
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt. Electronic address: walaa.abozaid@pharma.cu.edu.eg.
- Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates. Electronic address: aalbohy@sharjah.ac.ae.
Förderung
- Al-Azhar University
Zitieren
APA
Abdulrazik, B. S., Mohamady, S., Mahmoud, W. R., & Albohy, A. (2026). Investigations on isatin-pyrimidinone hybrids as novel lead compounds for selective inhibition of TrkA enzyme. Bioorganic Chemistry, 174, 109718. https://doi.org/10.1016/j.bioorg.2026.109718
Vancouver
Abdulrazik BS, Mohamady S, Mahmoud WR, Albohy A. Investigations on isatin-pyrimidinone hybrids as novel lead compounds for selective inhibition of TrkA enzyme. Bioorganic Chemistry. 2026;174:109718. doi:10.1016/j.bioorg.2026.109718
BibTeX
@article{Abdulrazik2026,
author = {Abdulrazik, Basma S and Mohamady, Samy and Mahmoud, Walaa R and Albohy, Amgad},
title = {Investigations on isatin-pyrimidinone hybrids as novel lead compounds for selective inhibition of TrkA enzyme},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {174},
pages = {109718},
doi = {10.1016/j.bioorg.2026.109718}
}
EUVIMED